drugset / Trial / NCT06697301
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Timeline
- Start
- 2025-05-22
- Primary completion
- 2035-12
- Completion
- 2040-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Resiquimod | Small molecule | — | — |